Igen Biolab Group
  • Home
  • About Us
  • Technology
  • Pipeline
  • Press
    • News
    • Press Releases
    • Events
    • Publications
  • Contact
  • English
    • Español
Select Page
Healthy gut microbiome improves success of cancer treatment

Healthy gut microbiome improves success of cancer treatment

by Igen BioLab Group | Mar 28, 2022 | News, Publications

The composition of the gut microbiome has been associated with clinical responses to immune checkpoint inhibitor (ICI) treatment, but there is limited consensus on the specific microbiome characteristics linked to the clinical benefits of ICIs. We performed shotgun...
Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients

Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients

by Igen BioLab Group | Mar 15, 2022 | News, Publications

This study aimed to analyse the diversity and taxonomic composition of the nasopharyngeal microbiota, to determine its association with COVID-19 clinical outcome. To study the microbiota, we utilized 16S rRNA sequencing of 177 samples that came from a retrospective...
The role of gut microbiome in cancer genesis and cancer prevention

The role of gut microbiome in cancer genesis and cancer prevention

by Igen BioLab Group | Mar 11, 2022 | News, Publications

Cancer is the second leading cause of fatalities at the global level, and the involvement of microbes in several diseases, including cancer is well known. The gut microbiome is known to have an essential role in the regulation of the host’s health and...
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

by Igen BioLab Group | Mar 3, 2022 | News, Publications

Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation of the gut...
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

by Igen BioLab Group | Mar 3, 2022 | News, Publications

Ample evidence indicates that the gut microbiome is a tumor-extrinsic factor associated with antitumor response to anti-programmed cell death protein-1 (PD-1) therapy, but inconsistencies exist between published microbial signatures associated with clinical outcomes....
« Older Entries

Recent Posts

  • Metagenomic Analyses Reveal Distinct Gut Microbiota Signature for Predicting the Neoadjuvant Chemotherapy Responsiveness in Breast Cancer Patients
  • Deciphering the Microbiome-Immunity-Cancer Axis
  • Targeting the gut and tumor microbiota in cancer
  • Healthy gut microbiome improves success of cancer treatment
  • Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients
  • Aviso legal
  • Política de Privacidad
  • Política de cookies
  • Facebook
  • Twitter
  • Instagram
  • RSS
Design by loComunicas

This website uses its own and third-party cookies in order to analyze the traffic generated for statistical purposes.

You can accept all cookies by clicking "Accept", reject all of them by clicking "Deny" or configure them by clicking "Settings".

For more information on how this site uses cookies and related technologies, you can read our Policy on Cookies

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly necessary cookies

Strictly necessary cookies must always be activated so that we can save your cookie settings preferences.

If you deactivate this cookie, we will not be able to save your preferences. This means that every time you visit this website you will have to activate or deactivate cookies again.

Third party cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, or the most popular pages.

Leaving this cookie active allows us to improve our website.

Please activate the strictly necessary cookies first so that we can save your preferences!

Cookies policy

More information about our cookie policy